Arne Kolstad

  • Head physician MD, PhD
  • +47 22 93 47 31

Curriculum vitae

ARNE KOLSTAD

 

born 4th of december 1958

Married, three children

MD, PhD

Consultant of Medical Oncology and Radiotherapy

  • MD University Hospital of Tromsø 1984 
  • PhD University of Tromsø 1989
  • Thesis entitled: “Variants of the HLA-system defined by human-human hybridoma antibodiese”
  • Speciality in medical oncology and radiotherapy 1996
  • Consultant The Norwegian Radium Hospital 1993-95
  • Consultant University Hospital of Tromsø 1995-2003
  • Assoc. Professor University of Tromsø 1999-2003
  • Consultant The Norwegian Radium Hospital 2003- present

Responsible for Lymphoma treatment and autologous stem cell transplants for Northern Norway 1995-2003. Etablished radioimmunotherapy in Tromsø and The Norwegian Radium Hospital. Etasblished allogeneic stem cell transplantation with reduced conditioning at the Norwegian Radium Hospital 2004. Member of the Norwegian and Nordic Lymphoma groups 1995-present.
Visiting researcher at the University of Michigan 1998-99, working with radioimmunotherapy
Tutor for PhD-student for thesis entiteled:
“Cancer therapies and impact on the immune system” 2002.

At present working at The Norwegian Radium Hospital as consultant with focus on lymphoma therapy and high-dose therapy with autologous and allogeneic stem cell transplantation.

 

Author network for Arne Kolstad by COREMINE medical


Publications 2019

Josefsson SE, Beiske K, Blaker YN, Førsund MS, Holte H, Østenstad B, Kimby E, Köksal H, Wälchli S, Bai B, Smeland EB, Levy R, Kolstad A, Huse K, Myklebust JH (2019)
TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma
Cancer Immunol Res, 7 (3), 355-362
DOI 10.1158/2326-6066.CIR-18-0351, PubMed 30659053

Publications 2018

Eskelund CW, Albertsson-Lindblad A, Kolstad A, Laurell A, Räty R, Pedersen LB, Geisler CH, Jerkeman M, Grønbæk K (2018)
Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma
Haematologica, 103 (11), e541-e543
DOI 10.3324/haematol.2018.194399, PubMed 29794145

Holte H, Beiske K, Boyle M, Trøen G, Blaker YN, Myklebust J, Kvaløy S, Rosenwald A, Lingjaerde OC, Rimsza LM, Smeland EB, Scott DW, Kolstad A (2018)
The MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy
Br J Haematol, 183 (2), 225-234
DOI 10.1111/bjh.15518, PubMed 30080252

Jerkeman M, Eskelund CW, Hutchings M, Räty R, Wader KF, Laurell A, Toldbod H, Pedersen LB, Niemann CU, Dahl C, Kuitunen H, Geisler CH, Grønbæk K, Kolstad A (2018)
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial
Lancet Haematol, 5 (3), e109-e116
DOI 10.1016/S2352-3026(18)30018-8, PubMed 29396091

Stokke C, Blakkisrud J, Løndalen A, Dahle J, Martinsen ACT, Holte H, Kolstad A (2018)
Pre-dosing with lilotomab prior to therapy with 177Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients
Eur J Nucl Med Mol Imaging, 45 (7), 1233-1241
DOI 10.1007/s00259-018-3964-9, PubMed 29470615

Publications 2017

Barzenje DA, Kolstad A, Ghanima W, Holte H (2017)
Long-term outcome of patients with solitary plasmacytoma treated with radiotherapy: A population-based, single-center study with median follow-up of 13.7 years
Hematol Oncol, 36 (1), 217-223
DOI 10.1002/hon.2415, PubMed 28393375

Blakkisrud J, Holtedahl JE, Løndalen A, Dahle J, Bach-Gansmo T, Holte H, Nygaard S, Kolstad A, Stokke C (2017)
Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan
J Nucl Med, 59 (4), 704-710
DOI 10.2967/jnumed.117.195347, PubMed 28848035

Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, Montano-Almendras CP, Husby S, Freiburghaus C, Ek S, Pedersen A, Niemann C, Räty R, Brown P, Geisler CH, Andersen MK, Guldberg P, Jerkeman M, Grønbæk K (2017)
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
Blood, 130 (17), 1903-1910
DOI 10.1182/blood-2017-04-779736, PubMed 28819011

Josefsson SE, Huse K, Kolstad A, Beiske K, Pende D, Steen CB, Inderberg EM, Lingjærde OC, Østenstad B, Smeland EB, Levy R, Irish JM, Myklebust JH (2017)
T Cells Expressing Checkpoint Receptor TIGIT Are Enriched in Follicular Lymphoma Tumors and Characterized by Reversible Suppression of T-cell Receptor Signaling
Clin Cancer Res, 24 (4), 870-881
DOI 10.1158/1078-0432.CCR-17-2337, PubMed 29217528

Wogsland CE, Greenplate AR, Kolstad A, Myklebust JH, Irish JM, Huse K (2017)
Mass Cytometry of Follicular Lymphoma Tumors Reveals Intrinsic Heterogeneity in Proteins Including HLA-DR and a Deficit in Nonmalignant Plasmablast and Germinal Center B-Cell Populations
Cytometry B Clin Cytom, 92 (1), 79-87
DOI 10.1002/cyto.b.21498, PubMed 27933753

Publications 2016

Albertsson-Lindblad A, Kolstad A, Laurell A, Räty R, Grønbæk K, Sundberg J, Pedersen LB, Ralfkiær E, Karjalainen-Lindsberg ML, Sundström C, Ehinger M, Geisler C, Jerkeman M (2016)
Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma
Blood, 128 (14), 1814-1820
DOI 10.1182/blood-2016-03-704023, PubMed 27354719

Barzenje DA, Holte H, Fosså A, Ghanima W, Liestøl K, Delabie J, Kolstad A (2016)
Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma
Leuk Lymphoma, 58 (3), 623-632
DOI 10.1080/10428194.2016.1204653, PubMed 27389974

Blakkisrud J, Løndalen A, Dahle J, Turner S, Holte H, Kolstad A, Stokke C (2016)
Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate
J Nucl Med, 58 (1), 55-61
DOI 10.2967/jnumed.116.180471, PubMed 27587710

Blakkisrud J, Løndalen A, Martinsen AC, Dahle J, Holtedahl JE, Bach-Gansmo T, Holte H, Kolstad A, Stokke C (2016)
Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan
J Nucl Med, 58 (1), 48-54
DOI 10.2967/jnumed.116.173922, PubMed 27493270

Eskelund CW, Kolstad A, Jerkeman M, Räty R, Laurell A, Eloranta S, Smedby KE, Husby S, Pedersen LB, Andersen NS, Eriksson M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Workman CT, Garde C, Elonen E, Brown P et al. (2016)
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau
Br J Haematol, 175 (3), 410-418
DOI 10.1111/bjh.14241, PubMed 27378674

Holm KL, Indrevaer RL, Myklebust JH, Kolstad A, Moskaug JØ, Naderi EH, Blomhoff HK (2016)
Myeloid cell leukaemia 1 has a vital role in retinoic acid-mediated protection of Toll-like receptor 9-stimulated B cells from spontaneous and DNA damage-induced apoptosis
Immunology, 149 (1), 62-73
DOI 10.1111/imm.12629, PubMed 27278254

Kolstad A, Pedersen LB, Eskelund CW, Husby S, Grønbæk K, Jerkeman M, Laurell A, Räty R, Elonen E, Andersen NS, Brown PD, Kimby E, Bentzen H, Sundström C, Ehinger M, Karjalainen-Lindsberg ML, Delabie J, Ralfkiær E, Fagerli UM, Nilsson-Ehle H, Lauritzsen GF, Kuittinen O, Niemann C, Geisler CH, Nordic Lymphoma Group (2016)
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years
Biol Blood Marrow Transplant, 23 (3), 428-435
DOI 10.1016/j.bbmt.2016.12.634, PubMed 28039078

Mensali N, Ying F, Sheng VO, Yang W, Walseng E, Kumari S, Fallang LE, Kolstad A, Uckert W, Malmberg KJ, Wälchli S, Olweus J (2016)
Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA
Oncoimmunology, 5 (5), e1138199
DOI 10.1080/2162402X.2016.1138199, PubMed 27467957

Myklebust JH, Brody J, Kohrt HE, Kolstad A, Czerwinski DK, Wälchli S, Green MR, Trøen G, Liestøl K, Beiske K, Houot R, Delabie J, Alizadeh AA, Irish JM, Levy R (2016)
Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling
Blood, 129 (6), 759-770
DOI 10.1182/blood-2016-05-718494, PubMed 28011673

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Østenstad B, Kvaløy S, Holte H (2016)
A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma
Br J Haematol, 173 (3), 432-43
DOI 10.1111/bjh.13965, PubMed 26914167

Publications 2015

Barzenje DA, Cvancarova Småstuen M, Liestøl K, Fosså A, Delabie J, Kolstad A, Holte H (2015)
Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years
PLoS One, 10 (7), e0131158
DOI 10.1371/journal.pone.0131158, PubMed 26147646

Blaker YN, Brodtkorb M, Maddison J, Hveem TS, Nesheim JA, Mohn HM, Kolstad A, Geisler CH, Liestøl K, Smeland EB, Holte H, Delabie J, Danielsen H (2015)
Computerized image analysis of the Ki-67 proliferation index in mantle cell lymphoma
Histopathology, 67 (1), 62-9
DOI 10.1111/his.12624, PubMed 25431344

Blix ES, Kildal AB, Bertelsen E, Waage A, Myklebust JH, Kolstad A, Husebekk A (2015)
Content of endothelial progenitor cells in autologous stem cell grafts predict survival after transplantation for multiple myeloma
Biol Blood Marrow Transplant, 21 (5), 840-7
DOI 10.1016/j.bbmt.2014.12.027, PubMed 25689789

Hoster E, Geisler CH, Doorduijn J, van der Holt B, Walewski J, Bloehdorn J, Ribrag V, Salles G, Hallek M, Pott C, Szymczyk M, Kolstad A, Laurell A, Räty R, Jerkeman M, Van't Veer M, Kluin-Nelemans JC, Klapper W, Unterhalt M, Dreyling M, Hermine O (2015)
Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials
Leukemia, 30 (6), 1428-30
DOI 10.1038/leu.2015.322, PubMed 26598017

Husby S, Ralfkiaer U, Garde C, Zandi R, Ek S, Kolstad A, Jerkeman M, Laurell A, Räty R, Pedersen LB, Pedersen A, Ehinger M, Sundström C, Karjalainen-Lindsberg ML, Delabie J, Clasen-Linde E, Brown P, Cowland JB, Workman CT, Geisler CH, Grønbæk K (2015)
miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator
Blood, 125 (17), 2669-77
DOI 10.1182/blood-2014-06-584193, PubMed 25736311

Kolstad A, Olweus J (2015)
"In situ" vaccination for systemic effects in follicular lymphoma
Oncoimmunology, 4 (7), e1014773
DOI 10.1080/2162402X.2015.1014773, PubMed 26140239

Smeland KB, Kiserud CE, Lauritzsen GF, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Kvaløy S, Holte H (2015)
Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway
Haematologica, 100 (6), e240-3
DOI 10.3324/haematol.2014.119214, PubMed 25682605

Publications 2014

Blaker YN, Eide MB, Liestøl K, Lauritzsen GF, Kolstad A, Fosså A, Smeland EB, Holte H (2014)
High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era
Leuk Lymphoma, 55 (10), 2319-27
DOI 10.3109/10428194.2013.871632, PubMed 24432894

Husøy MA, Brinch L, Tjønnfjord GE, Gedde-Dahl T, Heldal D, Holme PA, Dybedal I, Kolstad A, Akkök ÇA, Rollag H, Gaustad P, Bergan S, Egeland T, Josefsen D, Kvalheim G, Fløisand Y (2014)
[Allogeneic stem-cell transplantation in adults 1985-2012: results and development]
Tidsskr Nor Laegeforen, 134 (16), 1569-75
DOI 10.4045/tidsskr.13.1415, PubMed 25178233

Kolstad A, Kumari S, Walczak M, Madsbu U, Hagtvedt T, Bogsrud TV, Kvalheim G, Holte H, Aurlien E, Delabie J, Tierens A, Olweus J (2014)
Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma
Blood, 125 (1), 82-9
DOI 10.1182/blood-2014-07-592162, PubMed 25293773

Kolstad A, Laurell A, Jerkeman M, Grønbæk K, Elonen E, Räty R, Pedersen LB, Loft A, Bogsrud TV, Kimby E, Hansen PB, Fagerli UM, Nilsson-Ehle H, Lauritzsen GF, Lehmann AK, Sundstrom C, Karjalainen-Lindsberg ML, Ralfkiaer E, Ehinger M, Delabie J, Bentzen H, Schildt J, Kostova-Aherdan K, Frederiksen H, Brown Pde N et al. (2014)
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma
Blood, 123 (19), 2953-9
DOI 10.1182/blood-2013-12-541953, PubMed 24652994

Nordström L, Sernbo S, Eden P, Grønbaek K, Kolstad A, Räty R, Karjalainen ML, Geisler C, Ralfkiaer E, Sundström C, Laurell A, Delabie J, Ehinger M, Jerkeman M, Ek S (2014)
SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study
Br J Haematol, 166 (1), 98-108
DOI 10.1111/bjh.12854, PubMed 24684350

Publications 2013

Bersvendsen H, Kolstad A, Blystad AK, Aurlien E, Fosså A, Kvaløy SO, Holte H, Lauritzsen GF (2013)
Multimodal treatment with ALL-like chemotherapy, Auto-SCT and radiotherapy for lymphoblastic lymphoma
Acta Oncol, 53 (5), 680-7
DOI 10.3109/0284186X.2013.855816, PubMed 24237392

Dahle J, Repetto-Llamazares AH, Mollatt CS, Melhus KB, Bruland OS, Kolstad A, Larsen RH (2013)
Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma
Anticancer Res, 33 (1), 85-95
PubMed 23267131

Laurell A, Kolstad A, Jerkeman M, Räty R, Geisler CH (2013)
High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial
Leuk Lymphoma, 55 (5), 1206-8
DOI 10.3109/10428194.2013.825906, PubMed 23876100

Myklebust JH, Irish JM, Brody J, Czerwinski DK, Houot R, Kohrt HE, Timmerman J, Said J, Green MR, Delabie J, Kolstad A, Alizadeh AA, Levy R (2013)
High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells
Blood, 121 (8), 1367-76
DOI 10.1182/blood-2012-04-421826, PubMed 23297127

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Fluge Ø, Fosså A, Hammerstrøm J, Kolstad A, Loge JH, Maisenhølder M, Østenstad B, Kvaløy S, Holte H (2013)
High-dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008
Tidsskr Nor Laegeforen, 133 (16), 1704-9
DOI 10.4045/tidsskr.13.0243, PubMed 24005706

Smeland KB, Kiserud CE, Lauritzsen GF, Fosså A, Hammerstrøm J, Jetne V, Kolstad A, Kvalheim G, Loge JH, Løkeland T, Tangen JM, Holte H, Kvaløy S (2013)
High-dose therapy with autologous stem cell support for lymphoma--from experimental to standard treatment
Tidsskr Nor Laegeforen, 133 (16), 1735-9
DOI 10.4045/tidsskr.13.0319, PubMed 24005713

Publications 2012

Blix ES, Irish JM, Husebekk A, Delabie J, Forfang L, Tierens AM, Myklebust JH, Kolstad A (2012)
Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma
BMC Cancer, 12, 478
DOI 10.1186/1471-2407-12-478, PubMed 23072591

Blix ES, Irish JM, Husebekk A, Delabie J, Tierens AM, Myklebust JH, Kolstad A (2012)
Altered BCR and CD40 signalling are associated with clinical outcome in small lymphocytic lymphoma/chronic lymphocytic leukaemia and marginal zone lymphoma patients
Br J Haematol, 159 (5), 604-8
DOI 10.1111/bjh.12073, PubMed 23043253

Fløisand Y, Brinch L, Gedde-Dahl T, Tjønnfjord GE, Dybedal I, Holte H, Heldal D, Torfoss D, Aurlien E, Lauritzsen GF, Fosså A, Lehne G, Baggerød E, Kvalheim G, Egeland T, Bishop MR, Fowler DH, Kolstad A (2012)
Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation
Bone Marrow Transplant, 47 (12), 1552-7
DOI 10.1038/bmt.2012.63, PubMed 22522568

Geisler CH, Kolstad A, Laurell A, Jerkeman M, Raty R, Andersen NS, Pedersen LB, Eriksson M, Nordstrom M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundstrom C, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E, Nordic Lymphoma Grp (2012)
Nordic MCL2 Trial Update: 6-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC Plus autologous stem-cell support: still very long survival but late relapses do occur (vol 158, pg 355, 2012)
Br. J. Haematol., 158 (6), 815-816

Geisler CH, Kolstad A, Laurell A, Jerkeman M, Räty R, Andersen NS, Pedersen LB, Eriksson M, Nordström M, Kimby E, Bentzen H, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E, Nordic Lymphoma Group (2012)
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur
Br J Haematol, 158 (3), 355-62
DOI 10.1111/j.1365-2141.2012.09174.x, PubMed 22640180

Holte H, Leppä S, Björkholm M, Fluge O, Jyrkkiö S, Delabie J, Sundström C, Karjalainen-Lindsberg ML, Erlanson M, Kolstad A, Fosså A, Ostenstad B, Löfvenberg E, Nordström M, Janes R, Pedersen LM, Anderson H, Jerkeman M, Eriksson M (2012)
Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
Ann Oncol, 24 (5), 1385-92
DOI 10.1093/annonc/mds621, PubMed 23247661

Olweus J, Kolstad A (2012)
[Can the immune system target cancer?]
Tidsskr Nor Laegeforen, 132 (7), 784-5
DOI 10.4045/tidsskr.12.0156, PubMed 22511078

Publications 2011

Abrahamsen IW, Kjellevoll S, Greve-Isdahl M, Mensali N, Wälchli S, Kumari S, Loland BF, Egeland T, Kolstad A, Olweus J (2011)
T cells raised against allogeneic HLA-A2/CD20 kill primary follicular lymphoma and acute lymphoblastic leukemia cells
Int J Cancer, 130 (8), 1821-32
DOI 10.1002/ijc.26209, PubMed 21630262

Eide MB, Lauritzsen GF, Kvalheim G, Kolstad A, Fagerli UM, Maisenhölder M, Østenstad B, Fluge Ø, Delabie J, Aarset H, Liestøl K, Holte H (2011)
High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study
Br J Haematol, 152 (5), 600-10
DOI 10.1111/j.1365-2141.2010.08519.x, PubMed 21241276

Fosså A, Fiskvik IH, Kolstad A, Lauritzsen GF, Aurlien E, Blystad AK, Hole KH, Ikonomou IM, Holte H (2011)
Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosis
Ann Oncol, 23 (5), 1254-9
DOI 10.1093/annonc/mdr385, PubMed 21926399

Hadzidimitriou A, Agathangelidis A, Darzentas N, Murray F, Delfau-Larue MH, Pedersen LB, Lopez AN, Dagklis A, Rombout P, Beldjord K, Kolstad A, Dreyling MH, Anagnostopoulos A, Tsaftaris A, Mavragani-Tsipidou P, Rosenwald A, Ponzoni M, Groenen P, Ghia P, Sander B, Papadaki T, Campo E, Geisler C, Rosenquist R, Davi F et al. (2011)
Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases
Blood, 118 (11), 3088-95
DOI 10.1182/blood-2011-03-343434, PubMed 21791422

Yri OE, Torfoss D, Hungnes O, Tierens A, Waalen K, Nordøy T, Dudman S, Kilander A, Wader KF, Ostenstad B, Ekanger R, Meyer P, Kolstad A (2011)
Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment
Blood, 118 (26), 6769-71
DOI 10.1182/blood-2011-08-372649, PubMed 22058114

Publications 2009

Andersen NS, Pedersen LB, Laurell A, Elonen E, Kolstad A, Boesen AM, Pedersen LM, Lauritzsen GF, Ekanger R, Nilsson-Ehle H, Nordström M, Fredén S, Jerkeman M, Eriksson M, Väärt J, Malmer B, Geisler CH (2009)
Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma
J Clin Oncol, 27 (26), 4365-70
DOI 10.1200/JCO.2008.21.3116, PubMed 19652064

Geisler C, Kolstad A, Laurell A, Räty R, Nordic Lymphoma Group, Mantle Cell Lymphoma Subcommittee (2009)
Mantle cell lymphoma - does primary intensive immunochemotherapy improve overall survival for younger patients?
Leuk Lymphoma, 50 (8), 1249-56
DOI 10.1080/10428190903040030, PubMed 19562619

Geisler CH, Kolstad A, Laurell A, Räty R, Jerkeman M, Eriksson M, Nordström M, Kimby E, Boesen AM, Nilsson-Ehle H, Kuittinen O, Lauritzsen GF, Ralfkiaer E, Ehinger M, Sundström C, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E, Nordic Lymphoma Group (2009)
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
Blood, 115 (8), 1530-3
DOI 10.1182/blood-2009-08-236570, PubMed 20032504

Houot R, Goldstein MJ, Kohrt HE, Myklebust JH, Alizadeh AA, Lin JT, Irish JM, Torchia JA, Kolstad A, Chen L, Levy R (2009)
Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion
Blood, 114 (16), 3431-8
DOI 10.1182/blood-2009-05-223958, PubMed 19641184

Publications 2008

Bishop MR, Dean RM, Steinberg SM, Odom J, Pavletic SZ, Chow C, Pittaluga S, Sportes C, Hardy NM, Gea-Banacloche J, Kolstad A, Gress RE, Fowler DH (2008)
Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation
Ann Oncol, 19 (11), 1935-40
DOI 10.1093/annonc/mdn404, PubMed 18684698

Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, Eriksson M, Nordström M, Kimby E, Boesen AM, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Akerman M, Ehinger M, Sundström C, Langholm R, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E, Nordic Lymphoma Group (2008)
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
Blood, 112 (7), 2687-93
DOI 10.1182/blood-2008-03-147025, PubMed 18625886

Kolstad A (2008)
[Heart complications following cancer treatment]
Tidsskr Nor Laegeforen, 128 (2), 187-8
PubMed 18240394

Kolstad A, Tjønnfjord G, Jønsson V (2008)
High frequency of unrecognized indolent hematological disorders among HLA-matched siblings of patients with lymphoproliferative malignancies eligible for allo-SCT
Bone Marrow Transplant, 42 (6), 427-8
DOI 10.1038/bmt.2008.183, PubMed 18587433

Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, Huijgens PC, Kolstad A, d'Amore F, Gonzalez Diaz M, Petrini M, Sebban C, Zinzani PL, van Oers MH, van Putten W, Bischof-Delaloye A, Rohatiner A, Salles G, Kuhlmann J, Hagenbeek A (2008)
Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma
J Clin Oncol, 26 (32), 5156-64
DOI 10.1200/JCO.2008.17.2015, PubMed 18854568

Publications 2007

Kolstad A, Holte H, Fosså A, Lauritzsen GF, Gaustad P, Torfoss D (2007)
Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen
Haematologica, 92 (1), 139-40
DOI 10.3324/haematol.10564, PubMed 17229653

Kolstad A, Nome O, Delabie J, Lauritzsen GF, Fossa A, Holte H (2007)
Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma
Leuk Lymphoma, 48 (3), 570-6
DOI 10.1080/10428190601126610, PubMed 17454601

Micci F, Panagopoulos I, Tjønnfjord GE, Kolstad A, Delabie J, Beiske K, Heim S (2007)
Molecular cytogenetic characterization of t(14;19)(q32;p13), a new recurrent translocation in B cell malignancies
Virchows Arch, 450 (5), 559-65
DOI 10.1007/s00428-007-0407-6, PubMed 17406891

Publications 2006

Fowler DH, Odom J, Steinberg SM, Chow CK, Foley J, Kogan Y, Hou J, Gea-Banacloche J, Sportes C, Pavletic S, Leitman S, Read EJ, Carter C, Kolstad A, Fox R, Beatty GL, Vonderheide RH, Levine BL, June CH, Gress RE, Bishop MR (2006)
Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation
Biol Blood Marrow Transplant, 12 (11), 1150-60
DOI 10.1016/j.bbmt.2006.06.015, PubMed 17085308

Publications 2005

Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, Regan D, Kison P, Fisher S, Kroll S, Wahl RL (2005)
131I-tositumomab therapy as initial treatment for follicular lymphoma
N Engl J Med, 352 (5), 441-9
DOI 10.1056/NEJMoa041511, PubMed 15689582

Publications 2004

Husebekk A, Skaug K, Kolstad A, Dahl IM, Gutteberg T, Skogen B (2004)
Hepatitis B virus-infected peripheral blood progenitor cell harvests in liquid nitrogen freezer containing non-infectious products
Transfusion, 44 (6), 942-3
DOI 10.1111/j.1537-2995.2004.00379.x, PubMed 15157265

Kolstad A, Risberg T, Bremnes Y, Wilsgaard T, Holte H, Klepp O, Mella O, Wist E (2004)
Use of complementary and alternative therapies: a national multicentre study of oncology health professionals in Norway
Support Care Cancer, 12 (5), 312-8
DOI 10.1007/s00520-004-0590-9, PubMed 14767750

Pettersen KI, Veenstra M, Guldvog B, Kolstad A (2004)
The Patient Experiences Questionnaire: development, validity and reliability
Int J Qual Health Care, 16 (6), 453-63
DOI 10.1093/intqhc/mzh074, PubMed 15557355

Risberg T, Bremnes Y, Kolstad A, Holte H, Wist E, Mella O, Klepp O (2004)
[Should complementary therapies be offered in hospitals?]
Tidsskr Nor Laegeforen, 124 (23), 3078-80
PubMed 15586193

Risberg T, Kolstad A, Bremnes Y, Holte H, Wist EA, Mella O, Klepp O, Wilsgaard T, Cassileth BR (2004)
Knowledge of and attitudes toward complementary and alternative therapies; a national multicentre study of oncology professionals in Norway
Eur J Cancer, 40 (4), 529-35
DOI 10.1016/j.ejca.2003.11.011, PubMed 14962719

Publications 2003

Andersen NS, Pedersen L, Elonen E, Johnson A, Kolstad A, Franssila K, Langholm R, Ralfkiaer E, Akerman M, Eriksson M, Kuittinen O, Geisler CH, Nordic Lymphoma Group (2003)
Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant
Eur J Haematol, 71 (2), 73-80
DOI 10.1034/j.1600-0609.2003.00093.x, PubMed 12890145

Risberg T, Kolstad A (2003)
[Alternative medicine--attitudes and use among physicians, nurses and administrative staff employed in hospitals in northern Norway]
Tidsskr Nor Laegeforen, 123 (5), 604-6
PubMed 12683182

Risberg T, Kolstad A (2003)
[Mental distress and use of alternative medicine among cancer patients]
Tidsskr Nor Laegeforen, 123 (5), 607-9
PubMed 12683183

Risberg T, Kolstad A, Wist EA, Holte H, Mella O, Klepp O (2003)
[Should alternative therapists treat cancer--what is the opinion of oncology health personnel?]
Tidsskr Nor Laegeforen, 123 (21), 3059-61
PubMed 14618177

Publications 2002

Nordøy T, Aaberge IS, Husebekk A, Samdal HH, Steinert S, Melby H, Kolstad A (2002)
Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae
Med Oncol, 19 (2), 71-8
DOI 10.1385/MO:19:2:71, PubMed 12180483

Risberg T, Kolstad A, Cassileth BR (2002)
Use of alternative medicine among Norwegian cancer patients is associated with mental distress--a follow-up study
Acta Oncol, 41 (7-8), 646-51
PubMed 14651209

Risberg T, Kolstad A, Cassileth BR (2002)
Use of Alternative Medicine Among Norwegian Cancer Patients is Associated with Mental Distress - A Follow-up Study
Acta Oncol, 41 (7-8), 646-651
DOI 10.1080/028418602321028265, PubMed 28758867

Storvoll EE, Wichstrøm L, Kolstad A, Pape H (2002)
Structure of conduct problems in adolescence
Scand J Psychol, 43 (1), 81-91
DOI 10.1111/1467-9450.00271, PubMed 11885763

Publications 2001

Nordøy T, Husebekk A, Aaberge IS, Jenum PA, Samdal HH, Flugsrud LB, Kristoffersen AC, Holte H, Kvaløy S, Kolstad A (2001)
Humoral immunity to viral and bacterial antigens in lymphoma patients 4-10 years after high-dose therapy with ABMT. Serological responses to revaccinations according to EBMT guidelines
Bone Marrow Transplant, 28 (7), 681-7
DOI 10.1038/sj.bmt.1703228, PubMed 11704791

Nordøy T, Kolstad A, Tuck MK, Aaberge IS, Husebekk A, Kaminski MS (2001)
Radioimmunotherapy with iodine-131 tositumomab in patients with low-grade non-Hodgkin's B-cell lymphoma does not induce loss of acquired humoral immunity against common antigens
Clin Immunol, 100 (1), 40-8
DOI 10.1006/clim.2001.5050, PubMed 11414744

Publications 2000

Nordoy T, Kolstad A, Husebekk A (2000)
Persistent immunological changes 55 months after PBPCT. Is the restoration of immune function possible with a longer follow-up? Response
Bone Marrow Transplant., 26 (6), 708

Pedersen W, Kolstad A (2000)
Adolescent alcohol abstainers: Traditional patterns in new groups
Acta Sociol., 43 (3), 219-233

Snellingen T, Shrestha JK, Huq F, Husain R, Koirala S, Rao GN, Pokhrel RP, Kolstad A, Upadhyay MP, Apple DJ, Arnesen E, Cheng H, Olsen EG, Vogel M (2000)
The South Asian cataract management study: complications, vision outcomes, and corneal endothelial cell loss in a randomized multicenter clinical trial comparing intracapsular cataract extraction with and without anterior chamber intraocular lens implantation
Ophthalmology, 107 (2), 231-40
DOI 10.1016/S0161-6420(99)00008-1, PubMed 10690817

Publications 1999

Nordøy T, Kolstad A, Endresen P, Holte H, Kvaløy S, Kvalheim G, Husebekk A (1999)
Persistent changes in the immune system 4-10 years after ABMT
Bone Marrow Transplant, 24 (8), 873-8
DOI 10.1038/sj.bmt.1702006, PubMed 10516699

Risberg T, Kolstad A, Johansen A, Vingerhagen K (1999)
Opinions on and use of alternative medicine among physicians, nurses and clerks in northern Norway
In Vivo, 13 (6), 493-8
PubMed 10757043

Publications 1998

Husebekk A, Kolstad A, Dahl IM, Skogen B (1998)
[Decentralized high-dose cytostatic treatment with autologous stem cell support]
Tidsskr Nor Laegeforen, 118 (18), 2777-80
PubMed 9748807

Katsarou E, Kolstad A, Hadjiliadis N, Sletten E (1998)
H-1 NMR study on the interaction between trans-Cl2Pd(dipeptide)(2) (dipeptide is glyglyOH and gly-L-nvalOH) and the dodecanucleotide [d(CGCGAATTCGCG)](2)
J. Inorg. Biochem., 70 (3-4), 265-269

Kolstad A (1998)
Risk perception related to depletion of the ozone layer and UV-B radiation in the arctic
Int J Circumpolar Health, 57 Suppl 1, 596-600
PubMed 10093349

Publications 1996

Kolstad A (1996)
Imprisonment as rehabilitation: Offenders' assessment of why it does not work
J. Crim. Justice, 24 (4), 323-335

Kolstad A, Holte H, Kvaløy S, Jakobsen E, Erikstein B, Aurlien E, Kvalheim G, Bøhler PJ, Langholm R (1996)
[High-dose therapy with autologous stem cell support in malignant lymphoma and breast cancer. Experiences with hematopoietic stem cells isolate from blood]
Tidsskr Nor Laegeforen, 116 (21), 2547-51
PubMed 8928122

Steinkopf S, Nerdal W, Kolstad A, Sletten E (1996)
Sequence-selective interaction between mercury(II) ions and the DNA dodecamer [d(GCCGATATCGGC)]2 studied by 1H NMR spectroscopy
Acta Chem Scand, 50 (9), 775-82
DOI 10.3891/acta.chem.scand.50-0775, PubMed 8817868

Publications 1992

Kolstad A (1992)
Children's symptoms and items of behaviour. An epidemiological study of sociocultural aetiology
Acta Paedopsychiatr, 55 (2), 77-82
PubMed 1585805

Kolstad A, Toubert A, Weyl D, Jun G, Hannestad K (1992)
Mapping of an epitope defined by a human hybridoma antibody (TrD3): a new HLA-B supertype associated with a subset of HLA-Bw6
Hum Immunol, 34 (2), 77-84
DOI 10.1016/0198-8859(92)90032-I, PubMed 1385373

Publications 1991

Kolstad A (1991)
[Assessment and quality assurance of medical technology--Scandinavian cooperation]
Nord Med, 106 (2), 61-4
PubMed 2006098

Publications 1989

Kolstad A (1989)
Evaluation of medical equipment on the basis of users' experiences and hazard registration
Health Policy, 11 (1), 61-72
DOI 10.1016/0168-8510(89)90056-0, PubMed 10292207

Kolstad A, Bratlie A, Hannestad K (1989)
A cytotoxic human-human hybridoma antibody (TrC7) specific for HLA-A29
Tissue Antigens, 33 (5), 542-5
DOI 10.1111/j.1399-0039.1989.tb01705.x, PubMed 2552611

Kolstad A, Hannestad K (1989)
A supertypic HLA-DP specificity defined by two human-human hybridoma antibodies (TrB50; TrE11)
Hum Immunol, 25 (4), 247-56
DOI 10.1016/0198-8859(89)90087-6, PubMed 2788637

Kolstad A, Hannestad K, Vandvik B, Vartdal F (1989)
Multiple sclerosis patients have a high frequency of an HLA-DQ beta epitope defined by a human-human hybridoma antibody
Tissue Antigens, 33 (5), 546-9
DOI 10.1111/j.1399-0039.1989.tb01706.x, PubMed 2477915

Kolstad A, Johansen B, Hannestad K (1989)
Two HLA-DQ-specific human-human hybridoma antibodies (TrG6;TrC5) define epitopes also expressed by a transcomplementing hybrid DQ molecule (DQw7 alpha/DQw4 beta)
Hum Immunol, 24 (1), 15-29
PubMed 2464569

KOLSTAD A, JOHANSEN B, HANNESTAD K (1989)
2 HLA-DQ-SPECIFIC HUMAN HUMAN HYBRIDOMA ANTIBODIES (TRG6-TRC5) DEFINE EPITOPES ALSO EXPRESSED BY A TRANSCOMPLEMENTING HYBRID DQ MOLECULE (DQW7-ALPHA/DQW4-BETA)
Hum. Immunol., 24 (1), 15-29

Publications 1988

Kolstad A, Hagen H (1988)
[Where ought psychiatric patients be placed? A survey of ideal and realistic residential and therapeutic possibilities for patients in psychiatric hospitals]
Tidsskr Nor Laegeforen, 108 (4), 315-8
PubMed 3353927

KOLSTAD A, HAGEN H (1988)
WHERE DO PSYCHIATRIC-PATIENTS WANT TO STAY
Nord. Psykol., 40 (3), 161-170

Kolstad A, Hansen T, Hannestad K (1988)
A cytotoxic human-human hybridoma antibody (TrH6) specific for HLA-DRw52
Tissue Antigens, 31 (2), 90-7
DOI 10.1111/j.1399-0039.1988.tb02069.x, PubMed 2836964

Saetnan AR, Backe B, Kolstad A, Lamvik T (1988)
Look to Norway! (But not uncritically)
Int J Technol Assess Health Care, 4 (3), 359-74
PubMed 10312679

Publications 1987

Hansen T, Kolstad A, Mathisen G, Hannestad K (1987)
A human-human hybridoma (Tr7E2) producing cytotoxic antibody to HLA-DQw1
Hum Immunol, 20 (4), 307-20
DOI 10.1016/0198-8859(87)90021-8, PubMed 2449413

Hansen T, Kolstad A, Thorsby E, Hannestad K (1987)
A human-human hybridoma producing cytotoxic antibody to HLA-B15, cross-reacting with B17, B5, B35 and B18
Tissue Antigens, 29 (5), 246-56
PubMed 2821654

KOLSTAD A (1987)
JACK PLUS JILL EQUALS TROUBLE - YOUNG-PEOPLE AND SEX - NORWEGIAN - ERICSSON,K, LUNDBY,G, RUDBERG,M
Nord. Psykol., 39 (1), 71-73

Kolstad A, Hansen T, Hannestad K (1987)
A human-human hybridoma antibody (TrB12) defining subgroups of HLA-DQw1 and -DQw3
Hum Immunol, 20 (3), 219-31
DOI 10.1016/0198-8859(87)90105-4, PubMed 2830209

Publications 1986

KOLSTAD A (1986)
VIOLENCE AND CONFLICTS WITH ANIMALS AND MAN - NORWEGIAN - BJERKE,T
Nord. Psykol., 38 (3), 233-235

Publications 1985

Brilliant LB, Pokhrel RP, Grasset NC, Lepkowski JM, Kolstad A, Hawks W, Pararajasegaram R, Brilliant GE, Gilbert S, Shrestha SR (1985)
Epidemiology of blindness in Nepal
Bull World Health Organ, 63 (2), 375-86
PubMed 3874717

BRILLIANT LB, POKHREL RP, GRASSET NC, LEPKOWSKI JM, KOLSTAD A, HAWKS W, PARARAJASEGARAM R, BRILLIANT GE, GILBERT S, SHRESTHA SR, KUO J (1985)
EPIDEMIOLOGY OF BLINDNESS IN NEPAL
Bull. World Health Organ., 63 (2), 375-386

Schmidt-Melbye A, Kolstad A, Hannestad K (1985)
Antibodies to granulocytes detected by an indirect immunofluorescence method not requiring chemical modification of cells
Transfusion, 25 (2), 165-9
DOI 10.1046/j.1537-2995.1985.25285169213.x, PubMed 3885485

May 12, 2004 Page visits: 36406